Cause-specific mortality in adults with atopic dermatitis - 28/02/18
, Lone Skov, MD, PhD a, Alexander Egeberg, MD, PhD aAbstract |
Background |
Adult atopic dermatitis (AD) has been associated with several comorbidities, but cause-specific mortality risk is unknown.
Objective |
To examine cause-specific death rates and risk in adults with AD.
Methods |
We performed cross-linkage of nationwide health care and cause of death registers. Adult patients with AD were matched with 10 controls per study subject. We calculated incidence rates per 1000 person-years and hazard ratios (HRs) of cause-specific death with 95% confidence intervals (95% CIs) using Cox proportional hazards models.
Results |
A total of 8686 patients and 86,860 matched controls were studied. The risk for death due to any cause was significantly increased in patients with AD (HR 1.27, 95%CI 1.11-1.45). Significant causes included cardiovascular (HR 1.45; 95% CI 1.07-1.96), infectious (HR 3.71; 95% CI 1.43-9.60), and urogenital diseases (HR 5.51; 95% CI 1.54-19.80). No increased risk for death due to cancer, endocrine, neurologic, psychiatric, respiratory, or gastroenterologic disease was observed.
Limitations |
The results might not be generalizable to patients seen exclusively by primary care physicians.
Conclusion |
Adults with atopic dermatitis had slightly increased risk for death during follow-up. While the risk for death from cardiovascular, urogenital, and infectious diseases was slightly elevated among patients with AD, the absolute risk was very low.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, cause, death, mortality, risk
Abbreviations used : AD, CI, HR, ICD, SD
Plan
| Funding sources: Dr Thyssen is supported by an unrestricted grant from the Lundbeck Foundation. |
|
| Conflicts of interest: Dr Thyssen has attended advisory board meetings about atopic dermatitis therapy for Roche and Sanofi-Genzyme and been a speaker on atopic dermatitis for LEO Pharma. He has been a speaker for Sanofi-Genzyme. Dr Skov has received consultancy and/or speaker honoraria from Abbvie, Pfizer, and Leo Pharma; is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Leo Pharma, Eli Lilly, Celgene, and Novartis; and has received research funding from Novatis, Janssen, and Pfizer. Dr Egeberg has received research funding from Pfizer and Eli Lilly and honoraria as a consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. |
|
| Reprints not available from the authors. |
Vol 78 - N° 3
P. 506-510 - mars 2018 Retour au numéro
Article précédent
- The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab
- Amy S. Paller, Tali Czarnowicki, Yael Renert-Yuval, Kristen Holland, Thy Huynh, Muriel Sadlier, Maeve A. McAleer, Gary Tran, Gabrielle C. Geddes, Alan D. Irvine, Emma Guttman-Yassky
- Pityrosporum folliculitis: A retrospective review of 110 cases
- Brea Prindaville, Leah Belazarian, Nikki A. Levin, Karen Wiss
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?